Vergelijking
Eloralintide vs. Semaglutid
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Metabool
Metabool
CAS-nr.
geen gegevens
910463-68-2
Molecuulmassa
geen gegevens
4113.6 g/mol
Halfwaardetijd
geen gegevens
165 h
Sequentie
geen gegevens
modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerWerkingsmechanisme
Eloralintide
Eloralintide selectively activates amylin receptors (preferentially AMY1R) and promotes satiety. The approach targets weight loss via the amylin axis, complementary to or independent of GLP-1 agents.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane RCT
Studies
2
4
waarvan bij mensen
1
3
Geregistreerde effecten
2
3
Openstaande tegenstrijdigheden
0
1
Gedocumenteerde bijwerkingen
1
5
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Eloralintide and Semaglutid?
- Eloralintide is classified as "Metabool", while Semaglutid is classified as "Metabool". Eloralintide: Eloralintide is a selective, long-acting amylin receptor agonist from Eli Lilly for once-weekly subcutaneous use — under investigation for obesity, alone and combined with incretin therapy. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Eloralintide or Semaglutid?
- The highest available evidence level is "Humane RCT" for Eloralintide and "Humane RCT" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Eloralintide and Semaglutid in Germany and the United States?
- Duitsland: Eloralintide — Niet goedgekeurd, Semaglutid — Op recept. Verenigde Staten: Eloralintide — Niet goedgekeurd, Semaglutid — Op recept. These are factual summaries with source and review date on the individual pages.